News | Thrombectomy Devices | June 11, 2015

Aspire Thrombectomy Device Effective in Removing Clot

Patient presented with cold leg

Aspire, thrombectomy, C. Dorn Smith, aspirators, clot, cold leg, removal

Clot in femoral artery caused by atrial fibrillation


June 11, 2015 - C. Dorn Smith, M.D., vascular surgeon in Kingstree, South Carolina, was successful in using a new device to remove blood clots from a patient with a cold leg using the Aspire mechanical thrombectomy device.

The patient presented with a cold leg and in atrial fibrillation, and Smith performed an angiogram. The angiogram revealed a 30 mm occlusion in the common femoral artery. Patients with atrial fibrillation often produce a clot from the heart that then travels to other areas of the body. Smith made four passes with the Aspire mechanical thrombectomy device. The Aspire device removed the clot, which was evident on a completion angiogram.

"Patients presenting with a cold leg need treatment immediately," said Smith. "The Aspire device was simple to set up and effective in removing the clot. This is a valuable tool in our toolbox to treat cardiovascular disease."

The Aspire mechanical thrombectomy system allows clinicians to instantly start, stop, increase, decrease, pulse or maintain thrombectomy force during a procedure. Aspire mechanical aspirators also aspirate up to 280ml, almost 10 times more than basic syringe-based systems, without multiple messy and time-consuming catheter connections, disconnections, and re-connections to improve speed and performance.

The patented system is available by itself or in kits that include an over-the-wire or rapid exchange thrombectomy catheter. Aspire mechanical aspirators may also be connected to any thrombectomy catheter the clinician chooses.

For more information: www.controlmedtech.com


Related Content

News | Thrombectomy Devices

Nov. 3, 2025 — Penumbra, Inc. has announced additional results of the STORM-PE randomized controlled trial (RCT), which ...

Home November 07, 2025
Home
News | Thrombectomy Devices

Oct. 27, 2025 – Penumbra, Inc. has announced the results of the STORM-PE randomized controlled trial (RCT), which found ...

Home October 27, 2025
Home
News | Thrombectomy Devices

Sept. 2, 2025 — Imperative Care, Inc. has announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its ...

Home September 02, 2025
Home
News | Thrombectomy Devices

June 16, 2025 – Penumbra, Inc. recently announced the completion of enrollment in the STORM-PE clinical trial. This ...

Home June 16, 2025
Home
News | Thrombectomy Devices

March 24, 2025 — Imperative Care, Inc. recently announced U.S. Food and Drug Administration (FDA) 510(k) clearance of ...

Home March 24, 2025
Home
News | Thrombectomy Devices

Penumbra recently launched its Element Vascular Access System, a laser-cut hypotube sheath designed for venous ...

Home January 30, 2025
Home
News | Thrombectomy Devices

Nov. 5, 2024 —Penumbra, Inc. recently announced new data that demonstrate patients with intermediate-risk pulmonary ...

Home November 07, 2024
Home
News | Thrombectomy Devices

Sept. 24, 2024 — Thrombolytic Science, LLC (TSI) has announced that the U.S. Food and Drug Administration (FDA) has ...

Home September 24, 2024
Home
News | Thrombectomy Devices

Sept. 5, 2024 - Prolocor, Inc. and Slingshot Biosciences recently announced the publication in Bioanalysis of the ...

Home September 10, 2024
Home
News | Thrombectomy Devices

January 16, 2024 — Penumbra, Inc., a thrombectomy company, has recently secured CE Mark (Conformité Européenne) for its ...

Home January 16, 2024
Home
Subscribe Now